Luke Laffin, M.D.

Stories

Kaiser trial finds digital reminders raise statin refills modestly

Published commentary arguing the trial's main value is its research model

About one in five patients in a large Northern California health system had stopped refilling their statins. Kaiser Permanente sent 20,604 of them a secure portal message, a text, a nonsecure email, or nothing beyond usual communication, then counted who refilled.

Updated 1 hour ago

One-time CRISPR therapy keeps cholesterol lower for a full year in early trial

New Capabilities

As of September 2026: Leading the CTX310 clinical program at Cleveland Clinic

A single infusion of a CRISPR gene-editing therapy kept LDL cholesterol about 52% lower and triglycerides about 48% lower for a full year in a 15-patient trial. It is the longest durability data yet for in vivo CRISPR in heart disease.

Updated Sep 27

Notable Quotes

The principal contribution of ADHERE-ASCVD may not be the modest improvement in statin adherence, but the demonstration that important clinical questions can be tested rapidly and rigorously within existing health system infrastructure.

from Kaiser trial finds digital reminders raise statin refills modestly · Updated 1 hour ago

Building upon the initial data presented in November 2025, the durability of the lipid-lowering effect was impressive. It is encouraging that there were no serious safety events related to CTX310 in the trial and in the year following treatment.

from One-time CRISPR therapy keeps cholesterol lower for a full year in early trial · Updated Sep 27